Skip to main content

CARACTERIZACION DE BIOMARCADORES DE DISFUNCION DEL TEJIDO ADIPOSO Y DE ACTIVACIÓN DE MACRÓFAGOS PARA EL DIAGNÓSTICO EL ESTADIAJE DEL HIGADO GRASO NO ALCOHÓLICO ASOCIADO A DM2

PI21/00817

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Execution centre HOSPITAL GERMANS TRIAS I PUJOL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Link between Abdominal Obesity Indices and the Progression of Liver Fibrosis, Insights from a Population-Based Study

  • Julián, María Teresa|||0000-0003-2524-1823
  • Arteaga, Ingrid
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Pera, Guillem|||0000-0003-3188-7268
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Ruiz-Rojano, Irene
  • Casademunt-Gras, Elena
  • Chacón, Carla|||0000-0001-8524-6189
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
There is currently no available information on the correlation between abdominal obesity indices and the risk of liver fibrosis progression. We aimed to investigate the relationship between the body mass index (BMI), waist circumference (WC), and the visceral adiposity index (VAI) with the progression of liver fibrosis. The study also evaluated the association between these indices and the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and liver fibrosis. A total of 1403 subjects participated in the cross-sectional and longitudinal population-based study. Liver stiffness was assessed via transient elastography, at baseline and follow-up (median: 4.2 years). The subgroup with dysglycemia was also analyzed. In the cross-sectional study, the highest quartile of VAI, BMI ≥ 30 kg/m 2, and abdominal obesity showed significant associations with the prevalence of MASLD and liver fibrosis, as well as with fibrosis progression. However, VAI showed no association with MASLD incidence. Among the dysglycemic subjects, there was no observed association between VAI and the incidence of MASLD or the progression of fibrosis. In conclusion, the BMI, WC, and the VAI are associated with an increased risk of progression to moderate-to-advanced liver fibrosis in the general population. However, the VAI does not perform better than the BMI and WC measurement.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of Dietary Niacin on Metabolic Dysfunction-Associated Steatotic Liver Disease in Mediterranean Subjects, A Population-Based Study

  • Antentas Peraile, María|||0009-0005-8140-203X
  • Rojo López, Marina Idalia|||0000-0001-6748-3156
  • Vendrell Tito, Pau|||0009-0003-2020-5126
  • Granado-Casas, Minerva|||0000-0003-3447-5728
  • Genua, Idoia|||0000-0001-6834-561X
  • Fernández-Camins, Berta|||0000-0001-7535-6181
  • Rossell, Joana|||0000-0003-1500-6379
  • Niño-Narvión, Julia|||0000-0001-6514-0731
  • Moreira, Estefanía
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Ortega, Emilio|||0000-0002-2217-8905
  • Vlacho, Bogdan|||0000-0003-3768-8112
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
  • Julve i Gil, Josep|||0000-0002-6531-2246
Background: The impact of dietary niacin on metabolic dysfunction-associated steatotic liver disease (MASLD) is elusive. This sub-study aimed to investigate the relationship between dietary niacin intake and the presence of MASLD in participants from two Catalonian cohorts. Methods: A total of 222 subjects with MASLD were age- and sex-matched to 222 non-MASLD subjects. Dietary nutrients were analyzed using a validated food frequency questionnaire (FFQ). Dietary niacin and other nutrients were adjusted for total energy intake. MASLD was defined by a Fatty Liver Index (FLI) of.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects, A population-based study

  • Julián, María Teresa|||0000-0003-2524-1823
  • Ballesta Purroy, Sílvia|||0000-0001-8057-1804
  • Pera, Guillem|||0000-0003-3188-7268
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Soldevila i Madorell, Berta|||0000-0002-4582-4201
  • Caballería, Llorenç|||0000-0002-7990-0719
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Expósito, Carmen|||0000-0002-9246-3779
  • Martinez Escude, Alba|||0000-0003-0667-1609
  • Puig Domingo, Manuel|||0000-0002-6744-7195
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Torán, Pere
  • Cusi, Kenneth|||0000-0002-8629-418X
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Mauricio, Didac|||0000-0002-2868-0250
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
To investigate longitudinal changes in the liver stiffness measurement (LSM) in the general adult population without known liver disease and to describe its association with metabolic risk factors, with a special focus on subjects with non-alcoholic fatty liver disease (NAFLD) and dysglycemia. A longitudinal adult population-based cohort study was conducted in Catalonia. LSM was measured by transient elastography (TE) at baseline and follow-up (median: 4.2 years). Subgroup with NAFLD and dysglycemia were analyzed. Moderate-to-advanced liver fibrosis was defined as LSM ≥8.0 kPa and LSM ≥9.2 kPa respectively. Among 1.478 subjects evaluated, the cumulative incidence of LSM ≥8.0 kPa and ≥9.2 kPa at follow-up was 2.8% and 1.9%, respectively. This incidence was higher in NAFLD (7.1% for LSM ≥8.0 kPa and 5% for LSM ≥9.2 kPa) and dysglycemia (6.2% for LSM ≥8.0 kPa and 4.7% for LSM ≥9.2 kPa) subgroups. In the global cohort, the multivariate analyses showed that dysglycemia, abdominal obesity and atherogenic dyslipidemia were significantly associated with progression to moderate-to-advanced liver fibrosis. Female sex was negatively associated. In subjects with NAFLD, abdominal obesity and dysglycemia were associated with changes in LSM to ≥8.0 kPa and ≥9.2 kPa at follow-up. A decline in LSM value to <8 kPa was observed in 64% of those subjects with a baseline LSM ≥8.0 kPa. In this population study, the presence of abdominal obesity and dysglycemia were the main risk metabolic factors associated with moderate-to-advanced liver fibrosis development over time in general populations as well as in subjects with NAFLD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dysglycemia in young women attenuates the protective effect against fatty liver disease

  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Julián, María Teresa|||0000-0003-2524-1823
  • Pera, Guillem|||0000-0003-3188-7268
  • Caballería, Llorenç|||0000-0002-7990-0719
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Expósito, Carmen|||0000-0002-9246-3779
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Mauricio, Didac|||0000-0002-2868-0250
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
Sexual dimorphism has been reported in non-alcoholic fatty liver disease (NAFLD), similar to the sex differences evident with cardiovascular disease. Type 2 diabetes mellitus (T2D) significantly increases the risk and severity of NAFLD, but there is scarce information on whether T2D or altered glucose metabolism can modify the prevalence of NAFLD in men and women of reproductive age. To investigate the relationship between age, sex and NAFLD in subjects with and without dysglycemia. We analyzed 2,790 patients. NAFLD was characterized using established diagnostic criteria: one or more positive results on the fatty liver index and hepatic ultrasound. Liver fibrosis (liver stiffness measurement [LSM] ≥8.0 kPa) was assessed by Fibroscan ®. For analysis purposes, we included both T2D and prediabetes under the predefined condition of dysglycemia. The global prevalence of NAFLD was higher in men than in women (50% and 34%; P<0.001), and the prevalence increased with age in both sexes. Older women (≥ 50 years) had a higher prevalence than younger women (<50 years), both in the overall cohort and in non-dysglycemic subjects. In dysglycemic subjects, the prevalence of NAFLD was slightly higher in men (68% vs 61%, p=0.021); in younger subjects, there were no differences in the prevalence of NAFLD between men and women (68% vs 64%, respectively; p=0.635). We found an interaction between dysglycemia and female sex (odds ratio [OR] 1.6 95% confidence interval [CI] 1.0-2.4, p=0.030), and between and age ≥50 years (OR 0.6, 95% CI 0.3-1.0, p=0.046). The global prevalence of LSM ≥8.0 kPa was higher in men compared with women (8% vs 4%; p< 0.001). This prevalence increased with age, mainly in men. We did not find any association between liver fibrosis and age and gender. While the global prevalence of NAFLD is higher in men than in women across all ages, younger women with dysglycemia have a similar risk of developing NAFLD as men of a similar age. Therefore, the presence of dysglycemia may erase the protective effect of female sex against fatty liver disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nicotinamide Prevents Diabetic Brain Inflammation via NAD+-Dependent Deacetylation Mechanisms

  • Torres-Méndez, Jeimy Katherine|||0000-0001-6299-8222
  • Niño-Narvión, Julia|||0000-0001-6514-0731
  • Martinez-Santos, Patricia
  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Vázquez del Olmo, Tania
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Julián, María Teresa|||0000-0003-2524-1823
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Muñoz, Juan Pablo|||0000-0003-0912-4168
  • Rossell, Joana|||0000-0003-1500-6379
  • Julve i Gil, Josep|||0000-0002-6531-2246
This study investigated the effect of nicotinamide (NAM) supplementation on the development of brain inflammation and microglial activation in a mouse model of type 1 diabetes mellitus. C57BL/6J male mice, which were made diabetic with five consecutive, low-dose (55 mg/kg i.p.) streptozotocin (STZ) injections. Diabetic mice were randomly distributed in different experimental groups and challenged to different doses of NAM (untreated, NAM low-dose, LD, 0.1%; NAM high-dose, HD, 0.25%) for 25 days. A control, non-diabetic group of mice was used as a reference. The NAD+ content was increased in the brains of NAM-treated mice compared with untreated diabetic mice (NAM LD: 3-fold; NAM HD: 3-fold, p-value < 0.05). Immunohistochemical staining revealed that markers of inflammation (TNFα: NAM LD: -35%; NAM HD: -46%; p-value < 0.05) and microglial activation (IBA-1: NAM LD: -29%; NAM HD: -50%; p-value < 0.05; BDKRB1: NAM LD: -36%; NAM HD: -37%; p-value < 0.05) in brains from NAM-treated diabetic mice were significantly decreased compared with non-treated T1D mice. This finding was accompanied by a concomitant alleviation of nuclear NFκB (p65) signaling in treated diabetic mice (NFκB (p65): NAM LD: -38%; NAM HD: -53%, p-value < 0.05). Notably, the acetylated form of the nuclear NFκB (p65) was significantly decreased in the brains of NAM-treated, diabetic mice (NAM LD: -48%; NAM HD: -63%, p-value < 0.05) and inversely correlated with NAD+ content (r = -0.50, p-value = 0.03), suggesting increased activity of NAD+-dependent deacetylases in the brains of treated mice. Thus, dietary NAM supplementation in diabetic T1D mice prevented brain inflammation via NAD+-dependent deacetylation mechanisms, suggesting an increased action of sirtuin signaling.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

NAD+ Precursors and Intestinal Inflammation, Therapeutic Insights Involving Gut Microbiota

  • Niño-Narvión, Julia|||0000-0001-6514-0731
  • Rojo López, Marina Idalia|||0000-0001-6748-3156
  • Martinez-Santos, Patricia
  • Rossell, Joana|||0000-0003-1500-6379
  • Ruiz-Alcaraz, Antonio J.|||0000-0001-6913-0610
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Ramos-Molina, Bruno|||0000-0001-6804-5449
  • Mauricio, Didac|||0000-0002-2868-0250
  • Julve i Gil, Josep|||0000-0002-6531-2246
The oxidized form of nicotinamide adenine dinucleotide (NAD+) is a critical metabolite for living cells. NAD+ may act either as a cofactor for many cellular reactions as well as a coenzyme for different NAD+-consuming enzymes involved in the physiological homeostasis of different organs and systems. In mammals, NAD+ is synthesized from either tryptophan or other vitamin B3 intermediates that act as NAD+ precursors. Recent research suggests that NAD+ precursors play a crucial role in maintaining the integrity of the gut barrier. Indeed, its deficiency has been associated with enhanced gut inflammation and leakage, and dysbiosis. Conversely, NAD+-increasing therapies may confer protection against intestinal inflammation in experimental conditions and human patients, with accumulating evidence indicating that such favorable effects could be, at least in part, mediated by concomitant changes in the composition of intestinal microbiota. However, the mechanisms by which NAD+-based treatments affect the microbiota are still poorly understood. In this context, we have focused specifically on the impact of NAD+ deficiency on intestinal inflammation and dysbiosis in animal and human models. We have further explored the relationship between NAD+ and improved host intestinal metabolism and immunity and the composition of microbiota in vivo. Overall, this comprehensive review aims to provide a new perspective on the effect of NAD+-increasing strategies on host intestinal physiology.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The double burden, type 1 diabetes and heart failure-a comprehensive review

  • Julián, María Teresa|||0000-0003-2524-1823
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
Heart failure (HF) is increasing at an alarming rate, primary due to the rising in aging, obesity and diabetes. Notably, individuals with type 1 diabetes (T1D) face a significantly elevated risk of HF, leading to more hospitalizations and increased case fatality rates. Several risk factors contribute to HF in T1D, including poor glycemic control, female gender, smoking, hypertension, elevated BMI, and albuminuria. However, early and intensive glycemic control can mitigate the long-term risk of HF in individuals with T1D. The pathophysiology of diabetes-associated HF is complex and multifactorial, and the underlying mechanisms in T1D remain incompletely elucidated. In terms of treatment, much of the evidence comes from type 2 diabetes (T2D) populations, so applying it to T1D requires caution. Sodium-glucose cotransporter 2 inhibitors have shown benefits in HF outcomes, even in non-diabetic populations. However, most of the information about HF and the evidence from cardiovascular safety trials related to glucose lowering medications refer to T2D. Glycemic control is key, but the link between hypoglycemia and HF hospitalization risk requires further study. Glycemic variability, common in T1D, is an independent HF risk factor. Technological advances offer the potential to improve glycemic control, including glycemic variability, and may play a role in preventing HF. In summary, HF in T1D is a complex challenge with unique dimensions. This review focuses on HF in individuals with T1D, exploring its epidemiology, risk factors, pathophysiology, diagnosis and treatment, which is crucial for developing tailored prevention and management strategies for this population.